Key result
Cardiac-specific protein phosphatase 2A overexpression reduces myocardial glucose consumption ~41% vs wild-type mice.
Why the study?
PP2A accounts for roughly half of all cardiac serine/threonine phosphatase activity, leading authors to hypothesize that it modulates cardiac glucose uptake and metabolism in vivo.
Effect estimate: reduced by 41%
Absolute Event Rate: 4.2% vs 7.2%
p-value: p=<0.05
Cardiac-specific overexpression of PP2A impairs myocardial glucose metabolism in vivo, suggesting that elevated PP2A expression may be detrimental in heart failure by compromising myocardial energy production.
Does not support clinical metabolic targeting; leaves open PP2A as a hypothesis-generating regulator of cardiac glucose use.
Protein phosphatase 2A (PP2A) accounts for approximately half of all serine/threonine phosphatase activity in the mammalian heart. We hypothesised that PP2A, through dephosphorylation of key regulatory enzymes, modulates cardiac glucose uptake and metabolism in vivo. Using positron emission tomography (PET), we studied the uptake of 2-[ 18 F]fluoro-2-deoxy-D-glucose ([ 18 F]FDG) in living mice with cardiac-specific overexpression of the catalytic subunit of PP2A (PP2A-TG) as well as in littermate controls (wild-type, WT). Additionally, we analysed the expression of enzymes and transcription factors involved in cardiac glucose metabolism. Cardiac glucose consumption was reduced by 41% ( P < 0.05) in PP2A-TG mice relative to WT. Real-time quantitative polymerase chain reaction analysis revealed decreased gene expression of glycogen synthase 1 (− 26%, P < 0.05), glycogen phosphorylase (− 17%, P < 0.05), Mtor (-22%, P < 0.05), peroxisome proliferator-activated receptor gamma (Pparg), and its coactivator PGC-1α (-41% and − 28% respectively; both P < 0.05) in PP2A-TG hearts. Western blotting demonstrated increased protein expression of phosphoinositide 3-kinase (PI3K, 26%, P < 0.05), reduced expression of glycogen synthase (-34%, P < 0.05) and glycogen phosphorylase (-18%, P < 0.05), and enhanced phosphorylation of AKT (95%, P < 0.05) and glycogen synthase kinase-3β (GSK3β, 22%, P < 0.05) in PP2A-TG hearts. These findings indicate that PP2A impairs cardiac glucose metabolism in vivo through modulation of multiple components of glucose handling, including the PI3K/AKT signalling axis, glycogen metabolism, and PPARγ-dependent transcriptional regulation. The effects of PP2A appear to be predominantly indirect. Elevated PP2A expression may therefore be detrimental in heart failure by compromising myocardial energy production.
No takes yet. Share an insight, caveat, or question.
Hadová et al. (2026) studied Healthy (Wild-type vs Transgenic mice). Cardiac-specific overexpression of PP2A vs. Wild-type littermates was evaluated on Myocardial glucose consumption (Standardized Uptake Value) (reduced by 41%, p=<0.05). Cardiac-specific overexpression of protein phosphatase 2A reduced myocardial glucose consumption by 41% compared to wild-type mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: